AFT Pharmaceuticals Limited

NZSE:AFT Stock Report

Market Cap: NZ$288.4m

AFT Pharmaceuticals Future Growth

Future criteria checks 3/6

AFT Pharmaceuticals is forecast to grow earnings and revenue by 23.7% and 14.1% per annum respectively. EPS is expected to grow by 25.1% per annum. Return on equity is forecast to be 17.3% in 3 years.

Key information

23.7%

Earnings growth rate

25.1%

EPS growth rate

Pharmaceuticals earnings growth30.2%
Revenue growth rate14.1%
Future return on equity17.3%
Analyst coverage

Low

Last updated12 Dec 2024

Recent future growth updates

AFT Pharmaceuticals Limited (NZSE:AFT) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

May 25
AFT Pharmaceuticals Limited (NZSE:AFT) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Recent updates

AFT Pharmaceuticals Limited (NZSE:AFT) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Nov 17
AFT Pharmaceuticals Limited (NZSE:AFT) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny

It's Unlikely That The CEO Of AFT Pharmaceuticals Limited (NZSE:AFT) Will See A Huge Pay Rise This Year

Jul 26
It's Unlikely That The CEO Of AFT Pharmaceuticals Limited (NZSE:AFT) Will See A Huge Pay Rise This Year

AFT Pharmaceuticals Limited (NZSE:AFT) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

May 25
AFT Pharmaceuticals Limited (NZSE:AFT) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Does AFT Pharmaceuticals (NZSE:AFT) Deserve A Spot On Your Watchlist?

May 22
Does AFT Pharmaceuticals (NZSE:AFT) Deserve A Spot On Your Watchlist?

Is Now The Time To Put AFT Pharmaceuticals (NZSE:AFT) On Your Watchlist?

Oct 17
Is Now The Time To Put AFT Pharmaceuticals (NZSE:AFT) On Your Watchlist?

Should You Be Adding AFT Pharmaceuticals (NZSE:AFT) To Your Watchlist Today?

May 23
Should You Be Adding AFT Pharmaceuticals (NZSE:AFT) To Your Watchlist Today?

Is AFT Pharmaceuticals Limited (NZSE:AFT) Trading At A 50% Discount?

Dec 01
Is AFT Pharmaceuticals Limited (NZSE:AFT) Trading At A 50% Discount?

We Discuss Whether AFT Pharmaceuticals Limited's (NZSE:AFT) CEO Is Due For A Pay Rise

Jul 30
We Discuss Whether AFT Pharmaceuticals Limited's (NZSE:AFT) CEO Is Due For A Pay Rise

With AFT Pharmaceuticals Limited (NZSE:AFT) It Looks Like You'll Get What You Pay For

Jun 02
With AFT Pharmaceuticals Limited (NZSE:AFT) It Looks Like You'll Get What You Pay For

Should You Be Impressed By AFT Pharmaceuticals Limited's (NZSE:AFT) ROE?

Mar 20
Should You Be Impressed By AFT Pharmaceuticals Limited's (NZSE:AFT) ROE?

A Quick Analysis On AFT Pharmaceuticals' (NZSE:AFT) CEO Compensation

Feb 13
A Quick Analysis On AFT Pharmaceuticals' (NZSE:AFT) CEO Compensation

Are AFT Pharmaceuticals's (NZSE:AFT) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Jan 23
Are AFT Pharmaceuticals's (NZSE:AFT) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Does AFT Pharmaceuticals (NZSE:AFT) Have A Healthy Balance Sheet?

Jan 02
Does AFT Pharmaceuticals (NZSE:AFT) Have A Healthy Balance Sheet?

Should AFT Pharmaceuticals (NZSE:AFT) Be Disappointed With Their 89% Profit?

Dec 12
Should AFT Pharmaceuticals (NZSE:AFT) Be Disappointed With Their 89% Profit?

AFT Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Nov 21
AFT Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Earnings and Revenue Growth Forecasts

NZSE:AFT - Analysts future estimates and past financials data (NZD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/202729023N/A142
3/31/202625618N/A123
3/31/202521512N/A113
9/30/2024199121726N/A
6/30/2024197141827N/A
3/31/2024195161929N/A
12/31/2023185131221N/A
9/30/202317511413N/A
6/30/202316611312N/A
3/31/202315711212N/A
12/31/202214914412N/A
9/30/202214117613N/A
6/30/202213518714N/A
3/31/202213020914N/A
12/31/202112515712N/A
9/30/202112011510N/A
6/30/2021116906N/A
3/31/20211138-51N/A
12/31/20201105-43N/A
9/30/20201073-26N/A
6/30/20201077310N/A
3/31/202010612815N/A
12/31/201910011712N/A
9/30/2019941159N/A
6/30/201989415N/A
3/31/201985-3-21N/A
12/31/201884-7-5-1N/A
9/30/201883-11-8-4N/A
6/30/201882-12N/A-6N/A
3/31/201881-14N/A-9N/A
12/31/201779-14N/A-13N/A
9/30/201776-14N/A-16N/A
6/30/201773-16N/A-18N/A
3/31/201769-18N/A-19N/A
12/31/201667-18N/A-20N/A
9/30/201664-18N/A-21N/A
6/30/201664-16N/A-17N/A
3/31/201664-13N/A-14N/A
12/31/201563-13N/A-12N/A
9/30/201562-13N/A-10N/A
6/30/201559-13N/A-11N/A
3/31/201556-13N/A-13N/A
3/31/201449-1N/A0N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: AFT's forecast earnings growth (23.7% per year) is above the savings rate (3%).

Earnings vs Market: AFT's earnings (23.7% per year) are forecast to grow slower than the NZ market (23.9% per year).

High Growth Earnings: AFT's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: AFT's revenue (14.1% per year) is forecast to grow faster than the NZ market (4.5% per year).

High Growth Revenue: AFT's revenue (14.1% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: AFT's Return on Equity is forecast to be low in 3 years time (17.3%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/31 06:55
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

AFT Pharmaceuticals Limited is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John HesterBell Potter
Jack CrowleyCredit Suisse
Soo RomanoffEdison Investment Research